Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Hangzhou Tigermed Consulting Co., Ltd
  6. News
  7. Summary
    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO., LTD

(300347)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 500 million worth of its shares.

08/25/2021 | 08:33am EDT

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) announces a share repurchase program. Under the program, the company will repurchase up to CNY 500 million worth of class A shares. The shares will be repurchased at a maximum price of CNY 190 per share. The program will be funded by self-owned funds or self-raised funds. The shares will be used to implement the A share equity incentive scheme or A share employee stock ownership plan. The program is valid for 12 months from the date of approval of the board or end prematurely from the date on which a resolution to terminate to the share repurchase plan is passed by the Board.


© S&P Capital IQ 2021
All news about HANGZHOU TIGERMED CONSULTING CO., LTD
10/22Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ende..
CI
10/15Hangzhou Tigermed Consulting Co., Ltd Appoints Mr. Wu as an Executive Director
CI
10/11Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced..
CI
09/17Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes
CI
09/17Hangzhou Tigermed Consulting Co., Ltd Announces Changes in Chief Financial Officer
CI
09/13Cytovia Therapeutics, Inc. announced that it has received $45 million in funding from T..
CI
08/31Beijing Lüzhu Biotechnology Co., Ltd. announced that it has received $54.1 million in f..
CI
08/25HANGZHOU TIGERMED CONSULTING : Tigermed Logs Double-Digit Earnings Growth in H1 on Strong ..
MT
08/25Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 500 million w..
CI
08/25Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended ..
CI
More news
Financials
Sales 2021 4 415 M 692 M 692 M
Net income 2021 1 810 M 284 M 284 M
Net cash 2021 9 707 M 1 521 M 1 521 M
P/E ratio 2021 73,3x
Yield 2021 0,26%
Capitalization 136 B 21 355 M 21 358 M
EV / Sales 2021 28,7x
EV / Sales 2022 21,6x
Nbr of Employees -
Free-Float 66,8%
Chart HANGZHOU TIGERMED CONSULTING CO., LTD
Duration : Period :
Hangzhou Tigermed Consulting Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 164,02 CNY
Average target price 197,29 CNY
Spread / Average Target 20,3%
EPS Revisions
Managers and Directors
Xiao Chun Cao Chief Financial Officer, Executive Director & GM
Hao Wu Co-President & Executive Director
Xiao Li Shi Chairman-Supervisory Board
Xiao Ping Ye Chairman
Bi Yun Zheng Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HANGZHOU TIGERMED CONSULTING CO., LTD1.49%21 355
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455